




- (51) **International Patent Classification:**  
**A61K 38/17** (2006.01) **C07K 14/47** (2006.01)  
**A61P 3/12** (2006.01)
- (21) **International Application Number:**  
PCT/US2021/035161
- (22) **International Filing Date:**  
01 June 2021 (01.06.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
63/033,593 02 June 2020 (02.06.2020) US
- (71) **Applicants:** **MERCK PATENT GMBH** [DE/DE]; Frankfurt Strasse 250, 64293 Darmstadt (DE). **EMD SERONO RESEARCH & DEVELOPMENT INSTITUTE, INC.** [US/US]; 45A Middlesex Turnpike, Billerica, Massachusetts 01821 (US).
- (72) **Inventors; and**  
(71) **Applicants:** **WAX, Stephen Daniel** [US/US]; 76 Bourne Street, Newton, Massachusetts 02466 (US). **BASSI, Roberto** [IT/US]; 195 Tamal Vista Boulevard, Apt 208, Corte Madera, California 94925 (US). **GUEHRING, Hans** [DE/DE]; c/o Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **TEHLIRIAN, Christopher** [US/US]; 15 Whitney Road, Newton, Massachusetts 02460 (US).
- (72) **Inventor:** **KAO, Amy Hui-chien**; c/o EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, Massachusetts 01821 (US).
- (74) **Agent:** **MAYER, Mika R.** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004-2400 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) **Title:** METHODS RELATED TO THE TREATMENT OF IGA NEPHROPATHY

(57) **Abstract:** The present disclosure relates to methods related to the treatment of IgA nephropathy. More specifically, the present disclosure relates to methods for treating a patient having IgA nephropathy (IgAN), to methods for reducing the serum Gd-IgA1 level in a patient having IgA nephropathy (IgAN), to methods for reducing the proteinuria in a patient having IgA nephropathy, to methods for reducing the serum Gd-IgA1 level and the proteinuria in a patient having IgA nephropathy, and further related disclosure. Agents used in these methods are transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI)- immunoglobulin (Ig) fusion molecules (TACI-Ig/TACI-Fc fusion molecules) such as ataccept.

[Continued on next page]

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))